The efficacy and safety of fasudil hydrochloride, a novel protein kinase inhibitor, were evaluated for the treatment of cerebral vasospasm and associated cerebral ischemic symptoms in patients with ruptured cerebral aneurysm. This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV. For 14 days following surgery, patients were administered either 30 mg of fasudil hydrochloride by intravenous injection over a period of 30 minutes three times a day or 1 mg/hr of nimodipine by continuous intravenous infusion. Fasudil hydrochloride and nimodipine both showed inhibitory effects on cerebral vasospasm. The incidence of symptomatic vasospasm was five of 33 patients in the fasudil group and nine of 32 patients in the nimodipine group. Good recovery evaluated by the Glasgow Outcome Scale was achieved by 23 of 33 patients in the fasudil group and 19 of 34 patients in the nimodipine group. Both drugs significantly improved consciousness levels and neurological deficits such as aphasia. However, fasudil hydrochloride improved motor disturbance more than nimodipine. Adverse reactions occurred in 13 of 37 patients receiving fasudil hydrochloride and 15 of 35 patients receiving nimodipine. There were no serious adverse events in the fasudil group. The results of this clinical trial indicate that fasudil hydrochloride is a safe and efficient agent for suppressing cerebral vasospasm after subarachnoid hemorrhage surgery for ruptured cerebral aneurysm.
Introduction
Subarachnoid hemorrhage is a dangerous disease with a high mortality. Rebleeding and hydrocephalus, major complications of subarachnoid hemorrhage, have been rendered less dangerous by the adoption of early surgery and improvements in postoperative management techniques. However, late cerebral vasospasm, which develops a few days to 2 weeks after onset of the hemorrhage, is a major cause of death or deficits and remains an unsolved problem in the treatment of subarachnoid hemorrhage.
Cerebral vasospasm is thought to be triggered by the interactions of multiple factors derived from extravasated blood, and progressive and protracted arterial narrowing may occur as a chain reaction J. Zhao et al.
continues. The massive increase of intracellular calcium in the arterial smooth muscle cells is considered to be the cause of early vasoconstriction of cortical conducting vessels. 8) The molecular mechanism of vasospasm has now been elucidated. Phosphorylation of myosin light chain is one of the most important signal transduction pathways in the arterial smooth muscle contraction-relaxation processes. 4) Muscle contraction results from the phosphorylation of myosin light chain induced by myosin light chain kinase. Muscle relaxation results from dephosphorylation of phosphorylated myosin light chain by myosin light chain phosphatase. The activations of Rho kinase and myosin light chain kinase promote the phosphorylation of myosin light chain and cause the contraction of arterial smooth muscle. The activated Rho kinase phosphorylates the myosin-binding subunit of myosin light chain phosphatase and inhibits phosphatase activity. 10, 19, 28) Protein kinase C activates the contraction of smooth muscle cells by phosphorylating the actin-binding protein calponin. 13) Fasudil hydrochloride, the isoquinoline sulfonamide derivative hexahydro-1-(5-isoquinolinesulfonyl)-1H-1, 4-diazepine hydrochloride, is a new potent vasodilator discovered and developed in Japan. The mechanism of action is different from that of calcium channel blockers such as nimodipine, which are widely used clinically for the treatment of cerebral vasospasm. 1, [14] [15] [16] [17] [18] Fasudil hydrochloride inhibits protein kinases such as Rho kinase, myosin light chain kinase, and protein kinase C, resulting in the inhibition of myosin light chain phosphorylation. 7, 12, 25) Animal experiments demonstrated that fasudil hydrochloride antagonizes the cerebral blood vessel contracting effect of endothelin, 5) and dilates spastic cerebral artery in a dog cerebral hemorrhage model, 22, 27) resulting in decreased ischemic damage. 3, 20) The results of multi-center, prospective, randomized, double-blind trials using placebo as the control revealed that fasudil hydrochloride suppresses cerebral vasospasm after subarachnoid hemorrhage surgery, alleviates the subsequent cerebral ischemia, and improves the prognosis of patients. 26) The efficacy of fasudil hydrochloride may be related to the improvement of hemodynamic functions such as the cerebral blood flow, glucose metabolism, 23, 29) and the viscosity of red blood cells, 9) and the reduction of neutrophil-mediated damage by inhibition of superoxide anion production 2) and neutrophil migration. 21, 24) Furthermore, fasudil hydrochloride has a protective effect on the anoxic neurodegeneration of cultured hippocampal neuronal cells. 11) The drug was first marketed in 1995 and is currently in clinical use in Japan.
The present study evaluated the efficacy and safety of fasudil hydrochloride for suppressing cerebral vasospasm and subsequent cerebral ischemic symptoms following subarachnoid hemorrhage surgery, compared to nimodipine in a randomized open trial.
Materials and Methods

I. Patient population
A total of 72 patients who underwent postsubarachnoid hemorrhage surgery for ruptured cerebral aneurysms in five hospitals from October 1998 to October 2000 were randomly divided into the fasudil group (37 patients) and the nimodipine group (35 patients). Patients who met the following inclusion criteria were selected for this study: surgery was performed within 7 days after the onset of subarachnoid hemorrhage; computed tomography (CT) was performed before or within 48 hours after the operation and showed the presence of subarachnoid hematoma, high risk for the occurrence of vasospasm; age 20 years or older but younger than 70 years; first episode of ruptured cerebral aneurysm; and preoperative Hunt and Hess grades I-IV.
The demographic characteristics, diagnosis, Hunt and Hess grade, duration of operation, associated disease, etc. of the patients are shown in Table 1 . Various indices observed at the time of enrollment and before surgery showed no statistically significant difference between the two groups. Patients or their next of kin were given an explanation of the nature of the drug and the purpose of the trial, and consent was obtained for each patient prior to entrance into the trial. The present clinical trial was approved by the ethical committee and was carried out as instructed by the Department of Public Health of the People's Republic of China (1998) by the departments of neurosurgery of five hospitals in China.
The trial and observation period commenced from the onset of the disease and continued for 1 month. Adverse reactions appearing during the period of the clinical trial were observed and analyzed. All patients failing to complete the trial were treated as dropout cases. One patient (fasudil group) had exceeded the postoperative time limit. Three patients (2 fasudil group and 1 nimodipine group) died of severe postoperative conditions despite all rescue measures. Drug administration had to be discontinued because of decreased blood pressure in one patient (nimodipine group). One patient (fasudil group) withdrew from the trial by choice, and one Effect of Fasudil Hydrochloride on Cerebral Vasospasm patient (nimodipine group) asked to be discharged from the hospital during the period of drug administration to be treated locally.
II. Drug regimen
Fasudil hydrochloride (Eril injection; Asahi Kasei Pharma Corporation, Tokyo) was administered three times a day, with a dose of 30 mg at each administration. The drug was dissolved in 100 ml of physiological saline and infused intravenously over a period of 30 minutes. Nimodipine was administered by continuous intravenous infusion with a dose of 1 mg/hr. Drug administration was started within 24 hours of aneurysm surgery and was continued for 14 days.
III. Evaluation of efficacy and safety
The Glasgow Coma Scale was used to evaluate the level of consciousness. The degree of aphasia, and motor disturbance of the upper and lower extremities were evaluated and graded into classes 1-4 (class 1: normal; 2: communication and verbalization are possible but sometimes poor, arm and leg joints can move and be extended; 3: communication and verbal understanding is sometimes possible but generally impossible, shoulder elevation, bending of elbows, extending of legs, or bending of knees is possible; 4: communication and verbalization are completely impossible, prostrate stretching or bending only or no movement).
Neurological deterioration, either temporary or permanent, was considered to be due to vasospasm (symptomatic cerebral vasospasm) if all other potential causes such as surgery, hydrocephalus, intracranial rebleeding, seizure, infection, cardiopulmonary dysfunction, electrolyte imbalance, and metabolic disturbances had been excluded. 26) Vasospasm on cerebral angiography was graded as none (no spasm), mild (mild decrease in the vascular lumen), moderate (between mild and severe), and severe (the blood vessel became line-like or became almost completely obstructed).
The causes of newly appeared low density areas on CT after operation were analyzed. The appearance was considered to be due to cerebral blood vessel spasm if other factors such as brain damage, occlusion of artery or vein, hematoma, and hydrocephalus could be excluded. Low density areas on CT were evaluated as none, mild (distinctive infarction with diameter smaller than 1 cm), moderate (moderate infarction with diameter greater than 1 cm to infarction of the distribution of one blood vessel), high (multiple small moderate infarctions), and severe (large scale infarction extending over the distributions of two to three blood vessels or infarction of the distribution of the middle cerebral artery). The clinical outcome was evaluated according to the Glasgow Outcome Scale.
IV. Statistical analysis
Qualitative factors were compared with the x 2 test or the precision probability method, whereas quantitative factors were compared with the Wilcoxon rank test. Therapeutic efficacy was evaluated between groups with the Wilcoxon rank test and before and after comparison within a group with analysis of variance or the sign rank test. Severity of symptomatic cerebral vasospasm was compared with the precision probability method. The clinical outcome 1 month after the onset of disease was evaluated with the Wilcoxon rank test. The inci- Each value shows the mean ± standard deviation of classes 1-4. *p º 0.05, **p º 0.01: significantly different from assessment before treatment. Each value shows the number of patients, except where otherwise indicated. P value calculated by the precision probability method. 
Results
I. Evaluation of efficacy
The levels of consciousness in the two groups were significantly improved after drug administration, 12.8 ± 2.30 to 14.0 ± 2.08 in the fasudil group (p º 0.01) and 13.0 ± 2.15 to 13.8 ± 1.97 in the nimodipine group (p º 0.05). The fasudil group showed more significant improvement than the nimodipine group. The fasudil group showed significant improvement in the degree of aphasia (p º 0.01), and reduced motor disturbance in the upper and lower extremities (p º 0.05), whereas the nimodipine group showed only significantly improved degree of aphasia (p º 0.05) ( Table 2) .
The rate of occurrence of symptomatic cerebral vasospasm in the fasudil group was lower than that in the nimodipine group, but there was no statistically significant difference ( Table 3 ). The degree of angiographical cerebral vasospasm was not statistically significantly different between the two groups before operation (Table 4 ). The occurrences of more than moderate vasospasm in the patients with no vasospasm before operation were similar after the operation. The changes in degree of cerebral vasospasm observed before and after operation in both groups were also not significant. The difference in the degree of vasospasm observed before and after operation was also statistically not significant. 
Effect of Fasudil Hydrochloride on Cerebral Vasospasm
No low density areas of more than moderate severity due to vasospasm were present in either group before operation ( Table 5 ). The occurrence of such areas were similar at 1 month after operation in the fasudil group and the nimodipine group. No statistically significant difference was observed between before and after operation within the groups or between the two groups.
The functional outcome observed 1 month after the onset of disease is shown in Table 6 . The rate of good recovery was higher in the fasudil group than in the nimodipine group although the functional outcome was statistically not significant between the two groups.
II. Evaluation of safety
Changes in systolic and diastolic pressure were compared before the start of drug administration, and 15, 30, and 60 minutes after intravenous infusion of the drug. There was a slight decrease in the systolic pressure (136.1 ± 15.72 to 127.3 ± 16.68 mmHg) in the fasudil group, and slight decreases in systolic (143.4 ± 23.56 to 129.32 ± 22.06 mmHg) and diastolic pressure (86.3 ± 11.57 to 74.1 ± 11.95 mmHg) in the nimodipine group. These decreases were statistically significant (p º 0.01). Comparison of the blood pressure before drug administration and at day 14 of drug administration revealed decreases in the systolic pressure (137.9 ± 18.66 to 127.8 ± 20.10 mmHg) in the fasudil group, and both the systolic (138.7 ± 21.20 to 119.4 ± 12.55 mmHg) and diastolic pressure (83.9 ± 10.41 to 76.0 ± 7.89 mmHg) in the nimodipine group. These decreases were statistically significant (p º 0.05). Drug administration was not stopped in any of the patients in the fasudil group due to decreased blood pressure, whereas drug administration was stopped in one patient in the nimodipine group because blood pressure decreased to 78/39 mmHg.
Thirteen of the 37 patients (35.1%) in the fasudil group developed adverse reactions (16 episodes), whereas 15 of 35 patients (42.9%) in the nimodipine group developed adverse reactions (22 episodes). There was no marked difference in the occurrence of adverse reactions between the two groups. The liver function abnormality observed in both groups was transient and mild in most cases. Mild bleeding of the digestive tract appeared in one patient in the fasudil group on day 4 after the operation, probably caused by a stress ulcer and not related to the drug administration. Flushing of the face and chest related to administration of nimodipine appeared in two patients. One patient showed marked decrease in blood pressure and had to stop taking nimodipine.
Discussion
This study evaluated the efficacy and safety of fasudil hydrochloride for the treatment of cerebral J. Zhao et al.
vasospasm and induced cerebral ischemic symptoms following subarachnoid hemorrhage surgery, using nimodipine as the control. Both fasudil hydrochloride and nimodipine significantly improved the consciousness levels and the degree of aphasia after subarachnoid hemorrhage. Fasudil hydrochloride also significantly improved motor disturbance whereas nimodipine did not. The incidence of symptomatic cerebral vasospasm in the fasudil group was lower than that in the nimodipine group. Angiographical vasospasm of more than moderate severity was rare in both the fasudil and nimodipine groups. Low density areas due to vasospasm of more than moderate severity were also rare after 1 month in both the fasudil and nimodipine groups. The number of patients achieving good recovery was about two thirds in both the fasudil and nimodipine groups. There were no significant differences between the two groups.
Evaluation of the safety of the agents found only a slight decrease in systolic pressure in the fasudil group, whereas both systolic and diastolic pressure decreased in the nimodipine group. One patient even had to discontinue nimodipine administration because of dramatic decrease in blood pressure. Fasudil hydrochloride has a selective vaso-relaxant effect on cerebral arteries and can dilate spastic basilar arteries with relatively smaller decline in the systemic arterial blood pressure compared to calcium channel blockers. 6) In this trial, fasudil hydrochloride caused smaller declines in systemic arterial blood pressure than nimodipine. Adverse reactions were slightly but not significantly less common in the fasudil group.
This clinical trial demonstrated that fasudil hydrochloride suppressed cerebral vasospasm and associated cerebral ischemic symptoms. No severe adverse effects or reactions were detected. The effect of fasudil hydrochloride was equal to that of nimodipine, but further study of larger numbers of patients is required to clarify the superiority of this drug. Fasudil hydrochloride is a safe and effective agent for treating patients after subarachnoid hemorrhage surgery for ruptured cerebral aneurysm. This drug may provide a new therapeutic modality for treating patients after cerebral aneurysm surgery and for improving the functional prognosis of these patients.
Commentary
Fasudil hydrochloride inhibits protein kinases A, G, and C and myosin light-chain kinase, the final common pathway of smooth-muscle contraction. 1) By this mechanism of action, fasudil hydrochloride prevents vasospasm. Shibuya et al. 2) reported that intravenous administration of fasudil hydrochloride significantly reduced the incidence of both symptomatic and asymptomatic vasospasm after aneurysmal subarachnoid hemorrhage (SAH). The significance of this study is that it not only displayed the efficacy of fasudil hydrochloride for the prevention of vasospasm, but also compared its efficiency with nimodipine. The results tell us that the incidence of symptomatic vasospasm, incidence of low-density areas on CT, and clinical outcome is similar for both drugs. It is noteworthy that while nimodipine lowers both systolic and diastolic pressure, fasudil hydrochloride lowers only the systolic pressure. This has an important message, because the main drawback of nimodipine usage is a considerable drop in blood pressure in patients who are vulnerable to a change in blood pressure.
In this well designed randomized study, the authors demonstrate that intravenous fasudil hydrochloride is a safe and efficient agent for suppressing cerebral vasospasm after SAH. Fasudil hydrochloride is a very promising drug that should be studied in a larger number of patients to evaluate its precise role in the medical treatment of cerebral vasospasm.
